Your browser is no longer supported. Please, upgrade your browser.
Settings
EYEG EyeGate Pharmaceuticals, Inc. daily Stock Chart
EYEG [NASD]
EyeGate Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own14.57% Shs Outstand49.79M Perf Week3.77%
Market Cap12.20M Forward P/E- EPS next Y-0.23 Insider Trans- Shs Float38.51M Perf Month6.52%
Income-7.60M PEG- EPS next Q-0.05 Inst Own47.20% Short Float0.43% Perf Quarter-27.08%
Sales3.20M P/S3.81 EPS this Y67.10% Inst Trans1.75% Short Ratio0.32 Perf Half Y-48.96%
Book/sh0.23 P/B1.07 EPS next Y0.00% ROA-48.40% Target Price6.00 Perf Year-56.25%
Cash/sh0.12 P/C2.07 EPS next 5Y- ROE-69.30% 52W Range0.21 - 0.86 Perf YTD-47.32%
Dividend- P/FCF- EPS past 5Y12.60% ROI-122.80% 52W High-70.41% Beta2.09
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low21.18% ATR0.03
Employees11 Current Ratio7.20 Sales Q/Q145.50% Oper. Margin- RSI (14)49.84 Volatility11.62% 16.09%
OptionableNo Debt/Eq0.00 EPS Q/Q109.40% Profit Margin- Rel Volume0.27 Prev Close0.25
ShortableYes LT Debt/Eq0.00 EarningsMay 24 BMO Payout- Avg Volume519.04K Price0.25
Recom- SMA200.61% SMA50-2.28% SMA200-33.56% Volume72,639 Change3.88%
Feb-06-18Reiterated H.C. Wainwright Buy $5 → $3
Apr-07-16Initiated Noble Financial Buy $10
Feb-01-16Initiated Rodman & Renshaw Buy $10
Dec-23-15Initiated Chardan Capital Markets Buy $6
Nov-12-15Initiated Maxim Group Buy $11
Jun-26-19 06:55AM  EyeGate Announces First Patient Enrolled in PRK Pivotal Study ACCESSWIRE
Jun-05-19 10:00AM  EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study Zacks Small Cap Research +5.24%
Jun-03-19 06:55AM  EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study ACCESSWIRE +23.46%
May-14-19 06:55AM  EyeGate Pharma Receives Positive Nasdaq Listing Determination ACCESSWIRE
May-08-19 04:15PM  EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update ACCESSWIRE +8.72%
May-02-19 02:00PM  EYEG: EYEG Submits IDE to FDA Seeking Approval to Commence Pivotal PRK Study Zacks Small Cap Research
06:55AM  EyeGate Files IDE with FDA for PRK Pivotal Study ACCESSWIRE
Mar-28-19 10:00AM  EYEG: Our Take On EYEG Moving Towards OBG-PRK Pivotal Study Zacks Small Cap Research
Mar-26-19 06:55AM  EyeGate Confirms Path to De Novo Filing with FDA ACCESSWIRE -13.45%
Mar-01-19 04:05PM  EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update ACCESSWIRE
Jan-29-19 06:55AM  EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City GlobeNewswire
Jan-16-19 06:55AM  EyeGate Pharmaceuticals Announces Meeting Date with FDA GlobeNewswire -12.35%
Nov-30-18 12:30PM  EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE? Zacks Small Cap Research
Nov-21-18 08:45AM  Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power Discovering Underlying Factors of Influence GlobeNewswire +7.57%
Nov-14-18 11:20AM  Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity ACCESSWIRE
06:50AM  Todays Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals ACCESSWIRE
Nov-13-18 04:05PM  EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +34.66%
09:50AM  4 Healthcare Stocks Investors Are Watching In November ACCESSWIRE
06:55AM  EyeGate Pharma Announces Positive Results in Second PRK Study GlobeNewswire
06:55AM  EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study GlobeNewswire
Oct-02-18 06:55AM  EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care GlobeNewswire +25.37%
Sep-28-18 11:45AM  EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints Zacks Small Cap Research -15.16%
Sep-25-18 06:55AM  EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules GlobeNewswire
Sep-24-18 06:55AM  EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies GlobeNewswire
Sep-04-18 08:31AM  EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies GlobeNewswire -14.29%
08:30AM  EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis GlobeNewswire
Aug-29-18 08:30AM  EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-20-18 08:30AM  EyeGate Announces Enrollment of First Patient in PRK Pilot Study GlobeNewswire
Aug-07-18 08:30AM  EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf GlobeNewswire -8.31%
Aug-03-18 08:30AM  EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-26-18 09:30AM  EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off Zacks Small Cap Research -7.71%
09:20AM  EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Of Zacks Small Cap Research
Jul-24-18 08:30AM  EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel GlobeNewswire +5.85%
Jul-10-18 07:45AM  Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE -5.69%
Jun-22-18 08:30AM  EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel GlobeNewswire
Jun-11-18 07:00AM  Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia ACCESSWIRE
May-30-18 08:30AM  EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel GlobeNewswire
May-29-18 10:35AM  EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start Zacks Small Cap Research
May-25-18 09:37PM  Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Heres How It Performed Lately Simply Wall St.
May-22-18 08:30AM  EyeGate Addresses Majority of FDAs Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel GlobeNewswire
May-16-18 04:30PM  EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd GlobeNewswire +7.71%
May-11-18 08:30AM  EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-07-18 08:11AM  Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Simply Wall St.
Apr-17-18 04:30PM  EyeGate Announces Completion of $11.25 Million Public Offering GlobeNewswire +22.41%
Apr-13-18 07:00AM  EyeGate Announces $11.25 Million Public Offering GlobeNewswire -7.31%
Apr-11-18 08:30AM  EyeGate Issued New Patent for Iontophoretic Contact Lens Technology GlobeNewswire +25.11%
Apr-09-18 08:30AM  EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel GlobeNewswire -19.32%
Apr-06-18 08:30AM  EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis GlobeNewswire +20.48%
Mar-09-18 08:30AM  EyeGate Pharma To Participate At The 30TH Annual ROTH Conference GlobeNewswire
Mar-08-18 03:31PM  EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success? Simply Wall St. +6.42%
08:30AM  EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel GlobeNewswire
Mar-02-18 04:28PM  EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update GlobeNewswire
Feb-21-18 11:30AM  EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint Zacks Small Cap Research
Feb-07-18 08:30AM  EyeGate to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire +12.29%
Feb-05-18 10:20AM  What Spooked Eyegate Pharmaceuticals Inc Investors Today SmarterAnalyst -41.54%
08:30AM  EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery GlobeNewswire
Jan-19-18 06:55PM  Should You Worry About Eyegate Pharmaceuticals Incs (NASDAQ:EYEG) CEO Pay Check? Simply Wall St.
Jan-04-18 08:30AM  EyeGate Promotes Sarah Romano to Chief Financial Officer GlobeNewswire
Jan-02-18 03:19PM  With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry? Simply Wall St.
Dec-25-17 11:54AM  ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 25, 2017 Capital Cube
Dec-19-17 08:30AM  EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye GlobeNewswire
Dec-18-17 08:30AM  EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment GlobeNewswire
Dec-12-17 01:10PM  ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 12, 2017 Capital Cube
Nov-30-17 01:48PM  ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 30, 2017 Capital Cube
09:25AM  What Does Eyegate Pharmaceuticals Incs (EYEG) Share Price Indicate? Simply Wall St.
Nov-29-17 07:54AM  EyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 12:00PM  EYEG: Cataract Surgery Study Completes Enrollment, Topline Data Expected Q1 18 Zacks Small Cap Research
Nov-17-17 11:51AM  ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 17, 2017 Capital Cube
Nov-14-17 07:09PM  Is Eyegate Pharmaceuticals Incs (EYEG) Liquidity As Good As Its Solvency? Simply Wall St.
08:00AM  EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Nov-08-17 08:30AM  EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery GlobeNewswire
Nov-02-17 12:08PM  ETFs with exposure to EyeGate Pharmaceuticals, Inc. : November 2, 2017 Capital Cube
Nov-01-17 08:30AM  EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy GlobeNewswire
Oct-23-17 08:30AM  Eye Care Thought Leaders Join EyeGate Scientific Advisory Board GlobeNewswire
Oct-18-17 09:44AM  ETFs with exposure to EyeGate Pharmaceuticals, Inc. : October 18, 2017 Capital Cube
Sep-11-17 06:30AM  EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships GlobeNewswire
Sep-05-17 06:30AM  EyeGate Pharma to Present at the 19th Annual Rodman and Renshaw Global Investment Conference GlobeNewswire +16.67%
Aug-31-17 06:20PM  ETFs with exposure to EyeGate Pharmaceuticals, Inc. : August 31, 2017 Capital Cube
Aug-24-17 11:20AM  EyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-09-17 08:00AM  EYEG: Q2 Inline. Additional Trials Expected To Commence Zacks Small Cap Research
Aug-07-17 07:30AM  EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-01-17 07:30AM  EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery GlobeNewswire -8.96%
Jun-14-17 04:30PM  EyeGate Announces Completion of $10.0 Million Public Offering GlobeNewswire
Jun-09-17 07:00AM  EyeGate Announces $10.0 Million Public Offering GlobeNewswire
May-31-17 11:00AM  EYEG: Pipeline Progress Continues, Includes First Valeant Ocular Surgery Development Milestone Zacks Small Cap Research
May-22-17 08:25AM  Eyegate Pharma stock surges 11% after receiving Valeant milestone payment MarketWatch
07:30AM  EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients GlobeNewswire
May-08-17 08:30AM  EyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: CombiMatrix and Eyegate Pharmaceuticals Accesswire
May-04-17 07:30AM  EyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel GlobeNewswire
Mar-13-17 07:30AM  EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D. GlobeNewswire
Mar-10-17 07:31AM  EYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-02-17 09:30AM  EYEG: Several Major Development Milestones Expected in 2017 Zacks Small Cap Research
Mar-01-17 01:04PM  EYEGATE PHARMACEUTICALS INC Financials
Feb-25-17 10:25AM  Top Biopharma Movers of the Past Week 24/7 Wall St.
Feb-23-17 04:08PM  EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update GlobeNewswire
04:06PM  EYEGATE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Feb-22-17 09:45AM  Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS Accesswire
08:00AM  EyeGate Pharmaceuticals Licensing Deal Review and Breakdown Accesswire
Feb-21-17 05:25PM  Tiny Waltham biotech's market cap doubles after $103M Valeant licensing deal at bizjournals.com
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.